share_log

君实生物自愿披露关于特瑞普利单抗一线治疗黑色素瘤的新适应症上市申请获得受理的公告

Junshi Bio voluntarily disclosed a public announcement regarding the acceptance of its application for a new indication for Trelagliptin single antibody first-line treatment of melanoma.

SZSI ·  Aug 12
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more